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Abstract 22 
Tris(1-chloro-2-propyl) phosphate (TCIPP) is an emerging contaminantwhich is ubiquitous in 23 
the indoor and outdoor environment. Moreover, its presence in human bodyfluids and biota 24 
has been evidenced. Since no quantitative data exist on the biotransformation or stability of 25 
TCIPP in the human body, we performed an in vitro incubation of TCIPP with human liver 26 
microsomes (HLM) and human serum (HS). Two metabolites, namely bis(2-chloro-isopropyl) 27 
phosphate (BCIPP) and bis(1-chloro-2-propyl) 1-hydroxy-2-propyl phosphate (BCIPHIPP), 28 
were quantified in a kinetic study using HLM or HS (only BCIPP, the hydrolysis product) and 29 
LC-MS. The Michaelis-Menten model fitted best the NADPH-dependent formation of 30 
BCIPHIPP and BCIPP in HLM, with respective VMAX of 154 ± 4 and 1470 ± 110 31 
pmol/min/mg protein and respective apparent Km of 80.2 ± 4.4 and 96.1 ± 14.5 µM.  32 
Hydrolases, which are naturally present in HLM, were also involved in the production of 33 
BCIPP. A HS paraoxonase assay could not detect any BCIPP formation above 38.6 ± 10.8 34 
pmol/min/µL serum. Our data indicate that BCIPP is the major metabolite of TCIPP formed 35 
in the liver. To our knowledge, this is the first quantitative assessment of the stability of 36 
TCIPP in tissues of humans or any other species.Further research is needed to confirm 37 
whether these biotransformation reactions are associated with a decrease or increase in 38 
toxicity. 39 
 40 
Keywords 41 
Organophosphate flame retardant; biotransformation; liver; serum; clearance  42 
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Abbreviations 43 
BCIPHIPP: bis(1-chloroisopropyl) 1-hydroxyisopropyl phosphate 44 
BCIPP: bis (1-chloroisopropyl) phosphate 45 
HLM: human liver microsomes 46 
PFR: phosphate flame retardant 47 
QTOF: quadrupole-time-of-flight 48 
TCIPP: tris(1-chloroisopropyl) phosphate 49 
TRIS: tris (hydroxymethyl)aminomethane 50 
  51 
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1. Introduction 52 
Tris(1-chloro-isopropyl) phosphate (TCIPP) is an additive flame retardant which is used in 53 
polymers, such as polyurethane foams, and is used also as a replacement of tris(2-chloroethyl) 54 
phosphate (EU 2008). TCIPP has been reported as one of the predominant phosphate flame 55 
retardants (PFRs) in the indoor and outdoor environment (van der Veen and de Boer 2012), 56 
and its uptake in living organisms has been demonstrated by several studies (Sundkvist et al. 57 
2010, Greaves and Letcher 2014). In comparison to non-chlorinated PFRs, TCIPP could be 58 
more resistant to abiotic degradation processes (Kawagoshi et al. 2002, Meyer  and Bester 59 
2004). In the benthic food web, bioaccumulation has been suggested by Brandsma et al. 60 
(2015). Our group recently detected a suite of PFR metabolites including a hydroxylated 61 
metabolite of TCIPP in human urine (Van den Eede et al. 2015a). While the detection of PFR 62 
metabolites in humans does not necessarily imply that the parent compounds are 63 
bioaccumulative, it does imply that human exposure occurs. This is concerning, as little is 64 
known about the possible effects on human health of chronic exposure to PFRs like TCIPP. 65 
Atopic dermatitis was recently correlated with increasing dust levels of TCIPP in an 66 
epidemiological study (Araki et al. 2014). In vitro, agonistic activity towards the pregnane X 67 
receptor and increases in 17-β-estradiol and testosterone were noted as effects on the 68 
endocrine system (Kojima et al. 2013, Liu et al. 2012), yet no estrogenic effects were detected 69 
(Zhang et al. 2014). In animals, a possible interference with thyroid hormone axis for growth 70 
and development in chicken embryos by TCIPP was observed (Farhat et al. 2013), though in 71 
zebrafish limited neurobehavioral changes and no teratogenic or hormonal effects were 72 
reported for this flame retardant (Dishaw et al. 2014). 73 
While biomonitoring can assist in correlating human health parameters with exposure to 74 
TCIPP, urinary analysis of the TCIPP metabolite, bis(2-chloro-isopropyl) phosphate (BCIPP), 75 
has had little success in contrast to other PFR metabolites which were targeted in 76 
5 
 
epidemiological studies (Schindler et al. 2009, Van den Eede et al. 2013a, Butt et al. 2014, 77 
Dodson et al. 2014, Fromme et al. 2014). Based on the results of in vitro metabolism 78 
screening (Van den Eede et al. 2013b) and a biomonitoring study (Van den Eede et al. 2015a) 79 
we suggested that another metabolite, namely bis(2-chloro-isopropyl) hydroxy-isopropyl 80 
phosphate (BCIPHIPP), might be a more suitable biomarker than BCIPP for monitoring 81 
exposure to TCIPP.  However, a comparison based on quantitative data for both BCIPP and 82 
BCIPHIPP metabolites has not yet been made in vitro, nor in vivo to support this hypothesis.  83 
Investigation of the production rates of these metabolites and their contribution to TCIPP 84 
clearance, and insight in the involved metabolic processes is a first step towards obtaining 85 
factors for the conversion of urinary concentrations to exposure estimates. Additionally, such 86 
toxicokinetic measurements are helpful in estimating the degree of persistence and the rate of 87 
(de)toxification of this flame retardant in the human body (depending on the role of the 88 
metabolites in the toxicity mechanism).  89 
Liver is the major site of metabolism for many xenobiotics, where the majority of 90 
oxidative enzymes are expressed (Lipscomb and Poet 2008). Yet in the case of 91 
organophosphate triesters, hydrolytic enzymes such as paraoxonases could also be involved in 92 
biotransformation (Furlong et al. 2000). Paraoxonases, and more specifically PON1, have 93 
been  identified  as  the  responsible  enzymes  for  detoxification  of  the  toxic  “oxon”  metabolites  94 
of organophosphate pesticides, including diazoxon, chlorpyrifos-oxon, and paraoxon(Furlong 95 
et al. 2000). PON1 is expressed both in liver and in serum (Furlong et al. 2000) and catalyzes 96 
the hydrolysis reaction with formation of a dialkyl phosphate (diethyl phosphate for 97 
paraoxon) and an alcohol (4-nitrophenol for paraoxon). For TCIPP only the hepatic 98 
metabolism has been studied so far, either focusing on oxidative processes or not 99 
distinguishing between oxidative and hydrolytic reactions (EU 2008, Van den Eede et al. 100 
2013b, Abdallah et al. 2015). In order to provide a more complete dataset for integration in 101 
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pharmacokinetic models, it is necessary to investigate the stability of TCIPP in presence of 102 
liver and serum enzymes, such as PON1, and to confirm the extent of contribution of 103 
oxidative and hydrolytic enzymes to TCIPP degradation in vitro.  104 
There were five aims to our study: (i) to apply µ-LC-QTOF technology to screening 105 
TCIPP metabolites  formed by human liver microsomes (HLM), (ii) to investigate metabolite 106 
clearance in HLM by quantifying the production rates of BCIPP and BCIPHIPP, (iii) to 107 
compare the intrinsic clearance of BCIPP to that of BCIPHIPP and relate both to in vivo 108 
findings, (iv) to extrapolate the intrinsic in vitro hepatic clearance to in vivo hepatic clearance, 109 
and (v) and to investigate the extent of hydrolysis of TCIPP to BCIPP by serum enzymes. 110 
 111 
2. Materials and Methods  112 
2.1.Materials and Reagents 113 
Tris   (hydroxmethyl)   aminomethane   (TRIS),   β-Nicotinamide   adenine   dinucleotide   2′-114 
phosphate reduced tetrasodium salt hydrate (NADPH), CaCl2, paraoxon, and diphenyl 115 
phosphate-d10 (DPHP-d10) were purchased from Sigma Aldrich (Bornem, Belgium). TCIPP 116 
standard was acquired from Pfalz & Bauer (Waterbury, USA). BCIPP, bis(2-chloroethyl) 117 
phosphate-d8 (BCEP-D8), tris(2-chloroethyl) phosphate-d12 (TCEP-D12), and BCIPHIPP 118 
were synthesized at the Max Planck Institute (Göttingen, Germany). TCIPP was a mixture of 119 
three isomers, namely tris(1-chloro-2-propyl) phosphate, bis(1-chloro-2-propyl) 1-120 
chloropropyl phosphate, and bis(1-chloropropyl) 1-chloro-2-propyl phosphate. All other 121 
reference and internal standards were of analytical grade, BCIPHIPP was a mixture of 2 122 
isomers as described elsewhere (Van den Eede et al. 2015a). HLM pools were purchased from 123 
Xenotech LLC, a 50-donor pool was used for the metabolite screening assay (lot 1210267) 124 
and a 200-donor pool for the metabolism kinetics study (lot 1210347, appendix B). Surplus 125 
serum samples collected in the frame of another study (registered at http://clinicaltrials.gov/ 126 
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with number NCT01778868) were pooled for use. This study was approved by the Ethical 127 
Committee of the Antwerp University Hospital (Belgian Registry number B30020097009) 128 
and all participants provided their written informed consent. Serum from 15 patients was 129 
pooled and stored at -20°C until analysis. Acetonitrile (analytical grade) was obtained from 130 
Merck   KgA   Chemicals   (Darmstadt,   Germany)   and   ultrapure   water   (18.2   MΩ)   from   an  131 
ElgaLabWater water purification instrument (Saint Maurice, France). 132 
2.2.Biotransformation assays 133 
2.2.1. HLM screening assay 134 
Reaction mixtures contained 50 mM TRIS buffer adjusted to pH 7.4 at 37 °C and 100 μM 135 
TCIPP in a total volume of 0.98 mL (final concentrations). 20 μl of NADPH (1 mM final 136 
concentration) was repeatedly added (every 30 min) to ensure continued CYP activity. After 137 
120 min, reactions were quenched using 1 mL of ice-cold acetonitrile and by storing the tubes 138 
on ice. Either no HLM or no NADPH was added in the negative controls. 139 
2.2.2. Preliminary experiments to establish steady state conditions 140 
2.2.2.1.HLM 141 
Preliminary experiments were run to establish the steady state conditions by monitoring the 142 
formation of BCIPHIPP metabolite. Firstly, the optimal protein concentration was established 143 
using concentrations of 0.05 mg/mL up to 1.0 mg/mL HLM (final concentration). Secondly, 144 
the optimal incubation time was established starting from 0 to 15 minutes. Details on the 145 
preliminary experiments can be found in supporting information.  146 
2.2.2.2.Serum 147 
Incubation mixtures consisted of 100 mM TRIS buffer (adjusted to pH 8.5 at 37 °C), 2 mM 148 
CaCl2, and serum in a 0.5 to 3% concentration (v/v), in a final volume of 500 μl. Reactions 149 
were initiated by adding 100 μM of TCIPP or paraoxon (positive control) in acetonitrile (1% 150 
of total volume). After 10 min, reactions were stopped by adding 110 μl of 20 mM Na2EDTA 151 
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and 60 μl of 10% acetic acid in water. Diphenyl phosphate-d10 (20 ng) was added to 152 
paraoxon samples, and 20 ng of BCEP-d8 was added to the TCIPP incubations. 200 μl of 153 
methanol was added to paraoxon samples, after which samples were vortexed and 154 
centrifuged. Supernatants were filtered before analysis. Serum samples incubated with TCIPP 155 
were extracted on Oasis WAX SPE columns, to enrich the extracts for BCIPP and BCEP-d8 156 
based on a urine extraction protocol (Van den Eede et al. 2013a). Cartridges were conditioned 157 
with 2 mL methanol and 2 mL Milli Q water. After loading of the samples, cartridges were 158 
washed with 1 mL Milli Q water and BCIPP and BCEP-d8 were eluted with 2 mL of 5% 159 
NH4OH in methanol. The eluate was collected and evaporated under a gentle N2 stream until 160 
dryness. Extracts were reconstituted in 100 μl 15% methanol in water. 161 
2.2.3. Kinetic metabolism study (HLM) 162 
Initial rate conditions were selected based on BCIPHIPP formation, which was linear up to 163 
0.25 mg/mL protein (HLM) and 7.5 min. Therefore these conditions were selected for 164 
conduct of our HLM kinetic metabolism study. Reaction mixtures contained 50 mM TRIS 165 
buffer adjusted to pH 7.4 at 37 °C, HLM (0.25 mg/mL final protein concentration) and 1 to 166 
300 μM TCIPP in a total volume of 0.98 mL (final concentrations). For each substrate 167 
concentration, five replicates were prepared. All samples were pre-incubated in a shaking 168 
water bath at 37 °C for 5 min. The reaction was started by adding 20 μl of NADPH stock 169 
solution (1 mM, final concentration), and quenched after 5 min by 500 μl of ice-cold 170 
acetonitrile and storing the tubes on ice. A fixed amount of IS (250 ng TCEP-d12 and BCEP-171 
d8) was added to each tube before centrifugation (10 min at 3,500 rpm). The supernatant was 172 
transferred to a new set of tubes, evaporated to 1 mL using nitrogen gas and filtered through a 173 
0.45 μm nylon filter into HPLC glass vials. Characterization of PON activity in HLM under 174 
these conditions is described in supporting information  175 
2.3.Quality control (QC) 176 
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For the HLM assay, NADPH negative control samples consisted of 50 mM TRIS buffer, 177 
HLM (0.25 mg/mL final protein concentration) and 1 to 300 μM TCIPP (final concentrations) 178 
in a total volume of 1 mL (in triplicate). Enzyme negative control samples consisted of 50 179 
mM TRIS buffer, 1 mM NADPH and 1 to 300 μM TCIPP (final concentrations) in a total 180 
volume of 1 mL (three replicates for each substrate level). Blank samples (three replicates) 181 
consisted of 50 mM TRIS buffer and HLM (0.25 mg/mL final protein concentration) in a total 182 
volume of 0.98 mL. 183 
Recovery of BCIPP and BCIPHIPP in HLM incubation mixtures, and the recovery of BCIPP 184 
in serum incubation mixtures were tested as described in the supporting information.  185 
2.4.Instrumental analysis 186 
2.4.1. Screening with µ-LC-QTOF 187 
An Eksigent 200 µLC was coupled to an ABSciex Triple-ToF 5600 for screening of the 188 
TCIPP metabolites in HLM samples. Analytes were separated on a Halo C18 column (50 x 189 
0.5 mm, 2.7 µm) with a mobile phase of 5 mM ammonium acetate in water (A) and 190 
acetonitrile (B). The following gradient was used: 10% B was held for 0.5 min, followed by a 191 
linear increase to 30% B in 1 min (0.5 min hold), and then to 95% B in 1 min (0.6 min hold)  192 
at a flow rate of 50 µL/min. After each analysis the column was re-equilibrated at 10% B 193 
during 0.6 min. An electrospray ionization source was used with the following parameters: 194 
gas 1, gas 2, and curtain gas were set at 15, 40, and 30 L/min, respectively. A source 195 
temperature of 300 °C was used, and ion spray fragmentor voltage was set at 4500 (negative 196 
mode) or 5000 (positive mode). TOF range was set to acquire masses between 100.0000 and 197 
1000.0000 Da with an accumulation time of 250 msec. MS/MS spectra were recorded in IDA 198 
(information dependent acquisition) mode, with fixed collision energy of 35 V. 199 
2.4.2. Quantitative analysis 200 
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For the TCIPP kinetics studies in HLM and serum, extracts were analyzed on an Agilent 1290 201 
LC coupled to a 6460 triple quadrupole MS. Phenylhexyl column (100 x 2.1 x 2.6 µm, 202 
Phenomenex) was used for separation of the extracts. The mobile phase consisted of 5 mM 203 
ammonium acetate in water (A) and acetonitrile (B), with the following gradient conditions 204 
for HLM extracts: 10% B (0.5 min hold), increase to 30% B in 2.5 min (2 min hold), increase 205 
to 40% B in 5 min, followed by a sharp increase to 95% B (3.5 min hold), and equilibration at 206 
starting conditions for 3.5 min. A different gradient program was used for serum extracts: 5% 207 
B (0-2 min), 20% B (at 2.5 min), 30% B (4 min), 40% B (6 min), 95% B (11-11.5 min), and 208 
equilibration at starting conditions for 7 min. 209 
Flow rate was 0.3 mL/min, temperature 40 °C, injection volume 1 µL. The following MS 210 
parameters were used: gas temperature 325 °C, sheath gas heater 250 °C, gas flow 10 L/min, 211 
sheath gas flow 11 L/min, nebulizer pressure 35 psi, capillary and nozzle voltage 3500 and 0 212 
V, respectively. MRM transitions can be found in Table A1.  213 
2.5.Data analysis 214 
2.5.1. Statistics 215 
Linear and non-linear regression of the HLM and serum data was done using Graphpad Prism 216 
5 (GraphPad software, Inc). For HLM data, the following models were compared: Michaelis-217 
Menten (equation 1), Hill equation, and substrate inhibition (see SI). BCIPP concentrations in 218 
cofactor and enzyme negative control samples were also analyzed by linear regression. 219 
Selection of the most appropriate model was based on an F-test of the goodness of fit of each 220 
model. If the difference in fit between models was not significant (p>0.05), the simplest 221 
model was selected.More details can be found in Supplementary Information. 222 
 223 
𝒗 = 𝑽𝒎𝒂𝒙 ×[𝑺]
𝑲𝒎+[𝑺]                       (Equation 1, Michaelis-Menten model) 224 
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For the analysis of serum data, an F-test was used after regression to determine if the slope 225 
was  significantly  different  from  zero.  To  estimate  the  sensitivity  of  the  serum  assay,  Cohen’s  226 
d for minimal effect size (equation 2), was considered as the minimal net formation of BCIPP 227 
by serum enzymes.  228 
𝒙ഥ𝟏 − 𝒙ഥ𝟐 = 𝒅 ×  ට(𝒏𝟏−𝟏)×𝒔𝟏𝟐+(𝒏𝟐−𝟏)×𝒔𝟐𝟐𝒏𝟏+𝒏𝟐−𝟐   (Equation 2) 229 
2.5.2. In vitro-in vivo extrapolation 230 
Intrinsic clearance and extrapolation of in vitro data to in vivo data were calculated based on 231 
the following equations (Lipscomb and Poet 2008): 232 
𝐶𝐿𝑖𝑛𝑡 ,𝐿𝑀 = 𝑉𝑚𝑎𝑥𝐾𝑚   (Equation 3) 233 
𝐶𝐿𝑖𝑛𝑡 = 𝐶𝐿𝑖𝑛𝑡 ,𝐿𝑀  × 𝑚𝑔𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑎𝑙𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑔𝑙𝑖𝑣𝑒𝑟  (Equation 4) 234 
𝐶𝐿ℎ = 𝐶𝐿𝑖𝑛𝑡 ×𝑄𝐻𝐶𝐿𝑖𝑛𝑡 +𝑄𝐻    (Equation 5) 235 
Equation 3 represents the intrinsic in vitro clearance CLint,LM, equation 4 scales CLint,LM to the 236 
full liver, while equation 5 assumes the direct scaling approach as representative of in vivo 237 
hepatic clearance (Poulin et al. 2011), although this approach may overestimate the in vivo 238 
clearance in case of extensive plasma protein binding. In these equations, the following 239 
scaling factors were used: 34 mg/g microsomal proteins per g liver, 0.71 mL/min/g liver for 240 
hepatic clearance (QH) and a relative liver mass of 2.6 g liver/kg bodyweight (Lipscomb and 241 
Poet 2008).  242 
 243 
3. Results  244 
3.1.Micro-LC-QTOF 245 
Four metabolites were found within 3 ppm mass error margin (table A3, figure 1): BCIPP (2 246 
isomers), BCIPHIPP (2 isomers), a carboxyl-metabolite (2 isomers) and hydroxy-TCIPP (1 247 
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isomer), which were previously named BCIPP, TCIPP-M2, TCIPP-M1 and TCIPP-M3, 248 
respectively (Van den Eede et al. 2013b).  249 
Isomers were not completely separated (figure A1), because the µ-LC gradient program was 250 
not fully optimized in this quick screening assay. MS/MS spectra (figure A2) confirmed the 251 
general structure of the metabolites, by showing the protonated phosphate, mono-ester and 252 
sometimes di-ester fragments in positive ionization mode. TCIPP-M1 indicated two additional 253 
rearrangements, namely one to a mono-ester with additional loss of formic acid to an ethenyl 254 
side chain (m/z 124.9978) and one to a lactone structure (m/z 152.9944).  255 
3.2.Performance of kinetic HLM and serumassay 256 
3.2.1. HLM 257 
The method detection limit (MDL) in HLM samples was 10 ng/mL for BCIPP and 1.5 ng/mL 258 
for BCIPHIPP. Using the optimized initial rate conditions for the experiments, TCIPP-M1 259 
and TCIPP-M3 were undetectable, probably because of slower formation rates so that they 260 
could only be detected in the 2h screening assay. 261 
3.2.2. serum 262 
BCIPP formation in the serum assay did not show any significant increase with increasing 263 
enzyme concentrations in incubation mixtures. At 20 µM TCIPP, BCIPP levels in samples 264 
were not higher than in method blanks. At 100 µM TCIPP, BCIPP levels in samples with 265 
serum, buffer, and CaCl2 (cofactor) were not higher than in samples without serum enzymes. 266 
The slope of BCIPP formation versus enzyme concentration was not significantly different 267 
from 0 (p = 0.27). A careful estimation of the sensitivity of the serum assay (equation 1) 268 
indicated that BCIPP formation would be below 38.6 (SD 10.8) pmol/min/µL serum. 269 
Compared to the positive control, 4-nitrophenol formation from 100 µM paraoxon was on 270 
average 88.3 (SD 5.6) pmol/min/µL serum. 271 
3.3.Metabolism kinetics in HLM 272 
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BCIPP was detected in reaction mixtures and also in our negative control samples. A large 273 
variability in BCIPP concentrations in samples was observed due to its variable presence in 274 
negative control samples (20 to 40% of total concentration). While BCIPP concentrations 275 
versus substrate level followed a non-linear trend characterized by saturation in samples 276 
(figure 2), this trend was linear in negative controls (figure 3). After subtraction of negative 277 
control levels, Michaelis-Menten (equation 1) was the optimal model for non-linear 278 
regression of NADPH-dependent BCIPP formation with an associated VMAX of 1470 ± 110 279 
pmol/min/mg protein, and Km of 96.1 ± 14.5 µM.  280 
Linear regression of BCIPP concentrations versus substrate concentration in enzyme and 281 
cofactor negative controls indicated good fit with R² values of >0.95 for both curves. Both 282 
slopes were significantly different from 0 and also significantly different from each other (p 283 
values all <0.01, see Table A2 for more information), indicating involvement of hydrolases in 284 
HLM, though their reaction rates were not quantifiable due to variable BCIPP formation in 285 
enzyme negative control replicates. We tested paraoxonase activity in HLM to test the 286 
possibility of hydrolases being involved in the production of BCIPP. Paraoxon hydrolysis by 287 
HLM under the same conditions (using 100 µM substrate) was 64.5 pmol (4-288 
nitrophenol)/min/mg protein, which supports the possible involvement of hydrolases in HLM.  289 
BCIPHIPP was formed solely by CYP- or other NAPDH-dependent enzymes. When plotting 290 
reaction velocity versus substrate concentration, a typical Michaelis-Menten curve was 291 
obtained with Vmax of 153.5 ± 4.0 pmol/min/mg protein and Km of 80.2 ± 4.4 µM (figure 2). 292 
Production rate of BCIPHIPP was nearly tenfold lower than that of BCIPP, yet BCIPHIPP 293 
concentrations showed less variability in reaction mixtures as this metabolite was not present 294 
in negative control samples. As a result, the kinetics model that was predicted for BCIPHIPP 295 
had a lower standard error for constants such as apparent Km and Vmax.  296 
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Based on the Vmax and Km parameters, in vitro intrinsic clearance CLint,LM (equation 3) was 297 
estimated to be 15.3 ± 2.6 and 1.91 ± 0.12 µL/min/mg protein for BCIPP and BCIPHIPP, 298 
respectively. As pointed out elsewhere (Pelkonen and Turpeinen 2007), CLint,LMof different 299 
pathways can be summed resulting in 17.2 ± 2.6 µL/min/mg protein. After application of 300 
equation 4 and the scaling factor mentioned under the methods section, the intrinsic clearance 301 
would be 585 µL/min/g liver for TCIPP.  Using the direct scaling approach (equation 5) this 302 
would be comparable to 0.32 mL/min/g liver or 0.83 mL/min/kg bodyweight..  303 
 304 
4. Discussion 305 
4.1.Micro-LC-QTOF screening 306 
The qualitative profile of metabolites, namely BCIPHIPP as major metabolite, was 307 
comparable both to our previously published work (Van den Eede et al. 2013b) and to the 308 
findings of Abdallah et al. (2015). Although the latter did not report any presence of TCIPP-309 
M3, this could have been due to the lower substrate concentrations used as TCIPP-M3 gave 310 
only a minor signal in our samples. Aside from demonstrating the reproducibility of our 311 
previous findings, the major purpose of repeating the metabolite screening for TCIPP was to 312 
test the applicability of µ-LC-QTOF in rapid analysis of suspect compounds. With a low 313 
injection volume, and only a three minute gradient elution program we were able to detect the 314 
same metabolites with a slightly better mass accuracy compared to the HPLC-QTOF 315 
instrument conditions in our previous study (Van den Eede et al. 2013b). While Abdallah et 316 
al. (2015) also achieved rapid separation with an ultra-high performance-LC coupled to an 317 
Orbitrap instrument, a µ-LC-QTOF is less expensive in acquisition and maintenance. The 318 
application of µ-LC-QTOF to this small sample set can serve as an indication of how similar 319 
sensitivity and resolution can be achieved along with a reduction in analysis time and solvent 320 
consumption in screening for metabolites of environmental contaminants.   321 
15 
 
4.2.Hydrolysis by serum enzymes 322 
Although it did not seem likely that serum had a major influence on TCIPP metabolism, the 323 
sensitivity of our assay could be limited. Because of the low number of replicates, a lower 324 
standard deviation in the samples and negative controls were needed to distinguish a small 325 
catalytic effect of serum enzymes. Hence  the sensitivity threshold may have interfered with 326 
the detection of any BCIPP formation and we cannot exclude any extra-hepatic degradation of 327 
TCIPP in blood. On the other hand, paraoxon hydrolysis by serum enzymes was observed, 328 
therefore the assay in itself was valid. This obvious difference between the catalytic activity 329 
of the paraoxonase enzyme towards paraoxon and TCIPP may be explained by structure-330 
related differences, such as the absence of an aryl side chain, since paraoxonases are known to 331 
hydrolyze mainly dialkyl aryl phosphate structures (Testa and Krämer 2010). In spite of this  332 
lack of interaction between TCIPP and paraoxonases, we chose to test this enzyme family 333 
since to our knowledge, no other enzymes have been characterized in humans that are capable 334 
of hydrolyzing organophosphate triesters without being consumed in the reaction. 335 
4.3.Biotransformationof TCIPP in HLM 336 
The possible involvement of hydrolases in HLM in the formation of BCIPP is surprising 337 
considering the non-detectable BCIPP formation by serum enzymes.These contradictory 338 
results can have two explanations: either hydrolases with different characteristics or origin 339 
than paraoxonases are involved in TCIPP metabolism, or the serum assay did not achieve 340 
sufficient sensitivity to distinguish any effect of paraoxonases.As mentioned previously, 341 
degradation of TCIPP by serum enzymes cannot be ruled out.   342 
As for the extrapolation of the kinetics of TCIPP biotransformation in HLM to the whole 343 
liver, the estimated intrinsic in vivo clearance of TCIPP (0.585 mL/min/g liver) is more than 344 
80% of the average hepatic blood flow (section 2.5.2), suggesting that TCIPP is not a low 345 
clearance chemical (meaning intrinsic clearance <20% of hepatic blood flow) and that its 346 
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hepatic clearance is not flow-limited either. As a consequence, TCIPP is not likely to exhibit 347 
the same accumulating behavior in the human body as more apolarenvironmental 348 
contaminants, such as polychlorinated biphenyls or polybrominated diphenyl ethers 349 
(Darnerud et al. 2015). 350 
4.4.Comparison of findings to in vivotoxicokinetics in rat 351 
Exposure of rats to 14C-labeled TCIPP revealed quick absorption and distribution of TCIPP in 352 
the body, as after 5.7 h maximum concentrations of the radiolabel were found in the tissues 353 
(Minegishi et al. 1988). TCIPP was mostly found in the liver and the kidneys, followed by the 354 
lungs. The majority of the TCIPP radiolabel was excreted in urine (67% within one week) 355 
(Minegishi et al. 1988). No metabolite structures were identified or measured for comparison 356 
with clearance rates in this study, though its findings suggest that uptake of TCIPP in the liver 357 
occurs, which is a prerequisite for hepatic clearance. Therefore hepatic clearance could play 358 
an important role in elimination of TCIPP besides excretion. 359 
4.5.Comparison of findings to human biomonitoring data  360 
4.5.1. Human milk 361 
The hepatic clearance rates measured in this study were comparable to those of TBOEP (Van 362 
den Eede et al. 2015b). However, in pooled breast milk samples higher detection frequency 363 
and median levels of TCIPP were reported in comparison to TBOEP (Sundkvist et al. 2010), 364 
which could be explained by hightissue distribution, as observed in rats for TCIPP (Minegishi 365 
et al. 1988). Investigation of toxicokinetic processes, such as renal and biliary clearance, and 366 
tissue distribution in the human body, is required to confirm the accumulation potential of this 367 
FR .  368 
4.5.2. Human urine 369 
BCIPP   was   detected   only   in   a   minority   (≤30%)   of   urine   samples   in   several   studies   as  370 
mentioned in the introduction. While limited method sensitivity could have been a reason for 371 
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this observation in some cases, in others BCIPP was still rarely detected despite a lower 372 
method detection limit (Schindler et al. 2009, Dodson et al. 2014, Fromme et al. 2014). 373 
Another logical explanation could have been low exposure, which might be the case for the 374 
United States (Stapleton et al. 2009, Dodson et al. 2012). However, in Europe this scenario 375 
would be less likely since TCIPP has been reported as a predominant PFR in indoor dust and 376 
air (Fromme et al. 2014, Cequier et al. 2015, Brandsma et al. 2014). We did find BCIPHIPP 377 
recently in more than 90% of analyzed Australian urine samples at levels up to 9.4 ng/mL 378 
(Van den Eede et al. 2015a) even though dust levels of TCIPP in Australia were similar to 379 
those in Canada and the European mainland (Brommer, 2014). In light of the current findings, 380 
it seems that BCIPP is the major metabolite formed by liver enzymes, though two factors 381 
could explain the difficulty of detecting BCIPP in urine: (i) analytical difficulties, and (ii) 382 
possible pharmacokinetic processes interfering with its excretion in urine, such as protein 383 
binding, storage in tissues or other excretion pathways. Paired measurements of BCIPHIPP 384 
and BCIPP levels in urine and serum are needed to confirm this hypothesis.  385 
4.6.Role of biotransformation in toxicity of TCIPP 386 
To date, the toxicity of TCIPP and BCIPP or BCIPHIPP cannot be compared due to lack of 387 
data on these two metabolites.The biotransformation pathway to BCIPHIPP includes two 388 
intermediate structures (Abdallah et al. 2015) which could also exert toxic effects at the site of 389 
the liver. Consequently, we cannot state if the obtained clearance values represent a 390 
detoxification or bioactivation. Furthermore, the hydrolytic formation of BCIPP could 391 
produce 1-chloro-2-propanol as a byproduct. This chemical causedadverse effects on the liver 392 
in rats at doses of 100 mg/kg/day and higher during a period of fourteen weeks (NTP 1998), 393 
which is slightly higher than the low observed adverse effect level for TCIPP under similar 394 
conditions and toxicity endpoint (EU 2008). As far as the potential byproduct is concerned, 395 
hydrolysis of TCIPP would lead to a slight decrease in toxicity. 396 
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4.7.Limitations 397 
The major limitations of this study as mentioned above, are the absence of plasma protein 398 
binding data, which could result in an overestimation of the current value of hepatic 399 
clearance; and the limited ability of the serum assay to distinguish any BCIPP formation.  400 
Because not all four metabolites of TCIPP were detectable at the initial rate conditions in the 401 
HLM assay, our calculations were based only on the two major metabolites. This exclusion of 402 
the two other, but minor,metabolites may have impacted our estimation of the intrinsic 403 
clearance of TCIPP, leading to an underestimation. 404 
 405 
5. Conclusions 406 
This study is the first to present quantitative data on TCIPP metabolism in humans (or any 407 
other species). Our results indicated faster formation of the hydrolysis product BCIPP than the 408 
dechlorinated metabolite BCIPHIPP by hepatic enzymes. The role of serum hydrolases in 409 
TCIPP hydrolysis could not be confirmed, although hepatic hydrolases did contribute to 410 
BCIPP formation. More information is needed onthe roles of the studied metabolites BCIPP 411 
and BCIPHIPP in the toxicity of this flame retardant. 412 
 413 
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Figures 528 
 529 
 530 
Figure 1. Proposed structures of tris(1-chloro-2-propyl) phosphate (TCIPP) metabolites. 531 
BCIPP: bis(1-chloro-2-propyl) phosphate; BCIPHIPP: bis(1-chloro-2-propyl)1-hydroxy-2-532 
propyl phosphate; TCIPP-M1 and TCIPP-M3 were named according to the previous 533 
publication (Van den Eede et al. 2013b). Only the structures of BCIPP and BCIPHIPP (2nd 534 
isomer) were confirmed using nuclear magnetic resonance spectroscopy and authentic 535 
standards. 536 
 537 
  538 
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 539 
Figure 2. Formation of BCIPP (bis(1-chloro-2-propyl) phosphate; bottom panel) and 540 
BCIPHIPP (bis(1-chloro-2-propyl) 1-hydroxy-2-propyl phosphate; top panel) by NADPH-541 
dependent enzymes. TCIPP (tris(1-chloro-2-propyl) phosphate was incubated in the presence 542 
of 0.25 mg/ml human liver microsomes and 1 mM NADPH for 7.5 min at 37 °C. Y-axis: 543 
Metabolite formation rate (pmol/(min * mg microsomal protein). Triangles indicate average 544 
production rate (n = 5), while error bars indicate the standard deviation between replicas. 545 
 546 
  547 
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 548 
Figure 3. Comparison of BCIPP (bis(1-chloro-2-propyl) phosphate) levels in incubation 549 
samples of TCIPP (tris1-chloro-2-propyl) phosphate with human liver microsomes and/or 550 
buffer. Total BCIPP: BCIPP levels as a result of both enzymatic formation and chemical 551 
hydrolysis; BCIPP from enzymatic formation: sum of BCIPP due to NADPH-catalyzed 552 
reactions and due to enzymatic hydrolysis; BCIPP in negative control: chemical and 553 
enzymatic hydrolysis of TCIPP in absence of NADPH; chemical hydrolysis: BCIPP 554 
formation in presence of buffer alone. Symbols indicate average concentrations, error bars 555 
represent the standard deviation.. 556 
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